Patients with moderate to severe HS experienced sustained symptomatic and quality-of-life improvements with the monoclonal ...
The Indian pharmaceutical market (IPM) registered a 6.1 per cent value growth in October 2024, with major therapies showing ...
Kikuchi–Fujimoto disease (KFD), histiocytic necrotising lymphadenitis, is a benign and self-limiting disease characterised ...
Together with GSK, the Boston-based research team will ... pulmonary disease, amyloidosis, and dermatology, among other areas. The school’s 30 teaching affiliates include Boston Medical Center ...
Johnson & Johnson announced at its booth the China market launch of INVEGA HAFYERA, a medicine for the treatment of ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Maternal hidradenitis suppurativa (HS) was associated with ...
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial ...
GlaxoSmithKline Pharmaceuticals Limited is ... such as Anti-Infectives, Dermatology, Gynaecology, Diabetes, Oncology, Cardiovascular Disease and Respiratory Diseases. They also offer a range ...
From dermatology to pain management and beyond ... The major players in the market are Hisamitsu Pharmaceuticals, Bayer AG, Novartis AG, Galderma Holding SA, GlaxoSmithKline PLC, Johnson & Johnson ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback